Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | UGCG | Q16739 | 5/20 | 0.45 |
| ▸ | GBA2 | Q9HCG7 | 5/20 | 0.45 |
| ▸ | GBA1 | P04062 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | LCT | P09848 | 2/20 | 0.39 |
| ▸ | SI | P14410 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12903278 | 1.00 | MEN1 (0.62) | MEN1KMT2ATSHRUGCGGBA2 | |
| SCHEMBL15516358 | 1.00 | MEN1 (0.62) | MEN1KMT2ATSHRUGCGGBA2 | |
| SCHEMBL31549217 | 0.98 | MEN1 (0.60) | MEN1KMT2ATSHRUGCGGBA2 | |
| SCHEMBL8478562 | 0.98 | MEN1 (0.60) | MEN1KMT2ATSHRUGCGGBA2 | |
| SCHEMBL334897 | 0.95 | MEN1 (0.64) | MEN1KMT2ATSHRUGCGGBA2 | |
| SCHEMBL2186409 | 0.88 | MEN1 (0.68) | MEN1KMT2ATSHRUGCGGBA2 | |
| SCHEMBL29606950 | 0.88 | MEN1 (0.68) | MEN1KMT2ATSHRUGCGGBA2 | |
| SCHEMBL2186406 | 0.88 | MEN1 (0.68) | MEN1KMT2ATSHRUGCGGBA2 | |
| SCHEMBL334304 | 0.88 | MEN1 (0.68) | MEN1KMT2ATSHRUGCGGBA2 | |
| SCHEMBL8483039 | 0.85 | TSHR (0.58) | MEN1KMT2ATSHRUGCGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1131270-B1 | PROCESS FOR CONVERTING AN ALCOHOL TO THE CORRESPONDING FLUORIDE | 3M INNOVATIVE PROPERTIES CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1135450-A1 | CHIRAL LIQUID CRYSTAL COMPOUNDS HAVING A FLUORINATED TERMINAL PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1131270-A1 | PROCESS FOR CONVERTING AN ALCOHOL TO THE CORRESPONDING FLUORIDE | 3M Innovative Properties Company (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6248889-B1 | FORMING MIXTURE COMPRISING AT LEAST ONE FLUORINATED, SATURATED ALIPHATIC OR ALICYCLIC SULFONYL FLUORIDE AND AT LEAST ONE PRIMARY OR SECONDARY ALCOHOL, ADDING MOLAR EXCESS OF STRONG, APROTIC, NON-NUCLEOPHILIC HINERED ORGANIC BASE | 3M INNOVATIVE PROPERTIES COMPANY | 2001-06-19 | — | — | US | disclosed |
| US-6139924-A | CONTAINING A PYRIMIDINE RING | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000031003-A1 | PROCESS FOR CONVERTING AN ALCOHOL TO THE CORRESPONDING FLUORIDE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031210-A1 | CHIRAL LIQUID CRYSTAL COMPOUNDS HAVING A FLUORINATED TERMINAL PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | MEN1 2456/4885KMT2A 939/4885TSHR 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.